Akums Drugs Reports Strong Financial Growth and Record Sales in March 2025 Results
Akums Drugs & Pharmaceuticals has announced its financial results for the quarter ending March 2025, highlighting significant growth in Profit After Tax, which reached Rs 139.40 crore. Net sales also peaked at Rs 1,055.55 crore, while Earnings per Share hit Rs 9.64, indicating strong financial performance.
Akums Drugs & Pharmaceuticals has recently reported its financial results for the quarter ending March 2025, showcasing notable developments within the company. The evaluation changes reflect a positive shift, with the score rising to 11 from 6 over the past three months.The financial data indicates a significant growth in Profit After Tax (PAT), which reached Rs 139.40 crore, marking a substantial increase compared to the average PAT of Rs 35.71 crore from the previous four quarters. This trend suggests a strong near-term outlook for profitability. Additionally, net sales for the quarter hit Rs 1,055.55 crore, the highest recorded in the last five quarters, further supporting a favorable sales trajectory.
Earnings per Share (EPS) also reached a peak of Rs 9.64, indicating enhanced profitability and greater earnings for shareholders. However, it is worth noting that the non-operating income for the quarter was recorded at Rs 17.55 crore, the highest in five quarters, raising questions about the sustainability of income derived from non-business activities.
Overall, Akums Drugs & Pharmaceuticals is experiencing a period of positive financial performance, as reflected in the recent evaluation adjustments.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
